View:
Download DOC
Download PDF
Download XLS
Download XBRL
8-K
Talis Biomedical Corp0001584751false00015847512023-05-082023-05-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 08, 2023(May 04, 2023)

 

 

Talis Biomedical Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40047

46-3122255

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1100 Island Drive

Suite 101

 

Redwood City, California

 

94065

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 433-3000

 

3400 Bridge Parkway
Redwood City, California 94065

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TLIS

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 8.01 Other Events.

Effective as of May 4, 2023, the Board of Directors (the “Board”) of Talis Biomedical Corporation (the “Company”) appointed Ms. Kimberly Popovits, who has served as a member of the Board since March 2020, as Lead Independent Director of the Board in accordance with the Company’s Amended and Restated Bylaws.

In accordance with the Company’s non-employee director compensation policy (the “director compensation policy”), Ms. Popovits will receive additional annual cash compensation of $22,500 for her service as Lead Independent Director of the Board, payable quarterly in arrears on a pro-rata basis, and annual equity compensation grants to be determined by the Board each year.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit Number

Exhibit Title

104.1

Cover Page Interactive Data File (Embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Talis Biomedical Corporation

 

 

 

 

Date:

May 8, 2023

By:

/s/ Rebecca L. Markovich

 

 

 

Rebecca L. Markovich
Interim Chief Financial Officer